{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:22:31Z","timestamp":1776691351337,"version":"3.51.2"},"reference-count":64,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Children and adolescents with psoriasis can have severe and long-lasting disease requiring early and effective therapy. The range of associated comorbidities is comparable to adult patients with additional problems deriving from their growth and maturation. Therefore, tailored information and interdisciplinary teamwork is necessary to effectively manage pediatric psoriasis. Methods: We reflected on our experience with therapy management of children and adolescents with psoriasis coming to our university outpatient clinic and summarized the challenges and special features of these patients together with approved medications and recommendations for treatment. We present our algorithm for managing these patients in an interdisciplinary setting. Results: Children can develop psoriasis very early in their life, and they show specific patterns of skin involvement depending on age. Scores such as the cDLQI and the PASI help to quantify the clinical severity and burden of the disease, and the upgraded criteria should reflect that children\u2019s needs are different from adults\u2019. The choice of medication is limited to a few, but increasing approvals for children and the close exchange of information and preparations with pediatricians and other specialties before initiating systemic therapies are crucial for children to support compliance. We emphasize the focus on vaccinations and the treatment of chronic infections, e.g., the management of TBI, which is different from adults. Conclusions: With the increased options for the systemic treatment of children with psoriasis, clear and adapted information for the child, guardian and pediatrician is essential to assure a well-managed environment and to prevent the unnecessary termination of effective therapy.<\/jats:p>","DOI":"10.3390\/jcm13216307","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:53:43Z","timestamp":1729583623000},"page":"6307","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Therapy of Psoriasis in Children\u2014Proposal of an Algorithm for Interdisciplinary Teamwork"],"prefix":"10.3390","volume":"13","author":[{"given":"Nesrine","family":"Ben-Anaya","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Speth","sequence":"additional","affiliation":[{"name":"Clinic for Child and Adolescent Medicine (Kinder-UKE), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Scheidmann","sequence":"additional","affiliation":[{"name":"Pediatrics, Pediatric Pulmonology, Altona Children\u2019s Hospital of Hamburg (AKK), 22763 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3692","authenticated-orcid":false,"given":"Brigitte","family":"Stephan","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2340\/00015555-0770","article-title":"Co-morbidity and age-related prevalence of psoriasis\u2014Analysis of health insurance data in Germany","volume":"90","author":"Augustin","year":"2010","journal-title":"Acta Derm Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000381913","article-title":"Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema","volume":"231","author":"Augustin","year":"2015","journal-title":"Dermatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: A population-based study","volume":"62","author":"Tollefson","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhou, S., and Yao, Z. (2022). Roles of Infection in Psoriasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136955"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1468-3083.2010.03645.x","article-title":"No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used","volume":"24","author":"Jager","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"571912","DOI":"10.1155\/2013\/571912","article-title":"Psoriasis: Female skin changes in various hormonal stages throughout life--puberty, pregnancy, and menopause","volume":"2013","author":"Ceovic","year":"2013","journal-title":"Biomed Res. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2004.10.011","article-title":"Regulatory roles of sex hormones in cutaneous biology and immunology","volume":"38","author":"Kanda","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/bjd.14507","article-title":"The epidemiology of childhood psoriasis: A scoping review","volume":"174","author":"Thomas","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000377709","article-title":"Nail Psoriasis in Children: Common or Uncommon? Results from a 10-Year Double-Center Study","volume":"1","author":"Piraccini","year":"2015","journal-title":"Ski. Appendage Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000489635","article-title":"A Review on the Role of Inflammation in Attention-Deficit\/Hyperactivity Disorder","volume":"25","author":"Leffa","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1590\/abd1806-4841.20186981","article-title":"Impact of psoriasis in the quality of life of children, adolescents and their families: A cross-sectional study","volume":"93","author":"Salman","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hoeger, P., Kinsler, V., Yan, A., Harper, J., Oranje, A., Bodemer, C., Larralde, M., Luk, D., Mendiratta, V., and Purvis, D. (2020). Psoriasis: Classification, Scores and Diagnosis. Harper\u2019s Textbook of Pediatric Dermatology, Wiley-Blackwell. [4th ed.].","DOI":"10.1002\/9781119142812"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1590\/abd1806-4841.20131915","article-title":"Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders","volume":"88","author":"Weber","year":"2013","journal-title":"An. Bras. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3899\/jrheum.090482","article-title":"Monitoring methotrexate toxicity in juvenile idiopathic arthritis","volume":"36","author":"Kocharla","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","article-title":"Immunogenicity of biologic agents in juvenile idiopathic arthritis: A systematic review and meta-analysis","volume":"58","author":"Doeleman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2013.1078","article-title":"Association of pediatric psoriasis severity with excess and central adiposity: An international cross-sectional study","volume":"149","author":"Paller","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamadermatol.2014.324","article-title":"Excess adiposity preceding pediatric psoriasis","volume":"150","author":"Becker","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_20","unstructured":"Petty, R.E., Laxer, R.M., Lindsley, C.B., Wedderburn, L.R., Fuhlbrigge, R.C., and Mellins, E.D. (2021). Textbook of Pediatric Rheumatology: Juvenile Idiopathic Arthritis, Elsevier. [8th ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/art.22173","article-title":"Patients with juvenile psoriatic arthritis comprise two distinct populations","volume":"54","author":"Stoll","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/anr.1780320810","article-title":"Psoriatic arthritis in children","volume":"32","author":"Southwood","year":"1989","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0950-3579(94)80021-9","article-title":"Juvenile psoriatic arthritis","volume":"8","author":"Ansell","year":"1994","journal-title":"Baillieres. Clin. Rheumatol."},{"key":"ref_24","first-page":"1092","article-title":"Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm\u2013Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidit\u00e4t","volume":"19","author":"Nast","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_25","first-page":"959","article-title":"S2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen\u2013Kurzfassung Teil 2","volume":"17","author":"Eisert","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_26","first-page":"856","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents\u2013Short version part 1","volume":"17","author":"Eisert","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Oommen, P.T., and Sch\u00fctz, C. (2024, March 03). Deutsche S2k-Leitlinie, Therapie der Juvenilen Idiopathischen Arthritis: AWMF-Register Nr. 027\/020. Available online: https:\/\/register.awmf.org\/assets\/guidelines\/027-020l_S2k_Juvenile_Idiopathische_Arthritis_2020-10-verlaengert.pdf.","DOI":"10.1007\/s00112-020-00982-0"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Brunello, F., Tirelli, F., Pegoraro, L., Dell\u2019Apa, F., Alfisi, A., Calzamatta, G., Folisi, C., and Zulian, F. (2022). New Insights on Juvenile Psoriatic Arthritis. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.884727"},{"key":"ref_29","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Sur, L.M., Gaga, R., Duca, E., Sur, G., Lupan, I., Sur, D., Samasca, G., Lazea, C., and Lazar, C. (2021). Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis. Life, 11.","DOI":"10.3390\/life11050398"},{"key":"ref_31","unstructured":"U.S. Food & Drug Administration (2024, September 03). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=208246."},{"key":"ref_32","unstructured":"European Medicines Agency (2024, September 03). Xeljanz: EMA\/351521\/2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz."},{"key":"ref_33","unstructured":"Drugs.com (2024, February 01). Abbott Receives FDA Approval for Humira (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis. Available online: https:\/\/www.drugs.com\/newdrugs\/abbott-receives-fda-approval-humira-adalimumab-polyarticular-juvenile-idiopathic-arthritis-851.html."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","article-title":"Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn\u2019s Disease","volume":"201","author":"Horneff","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_35","unstructured":"Drugs.com (2024, February 01). Humira FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/humira.html."},{"key":"ref_36","unstructured":"Drugs.com (2024, March 03). FDA Approves Expanded Use of Enbrel (Etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-expanded-enbrel-etanercept-children-chronic-moderate-severe-plaque-psoriasis-4451.html."},{"key":"ref_37","unstructured":"Drugs.com (2024, March 03). Enbrel FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/enbrel.html."},{"key":"ref_38","unstructured":"Drugs.com (2024, March 03). FDA Approves Stelara (Ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-stelara-ustekinumab-pediatric-patients-moderate-severe-plaque-psoriasis-5315.html."},{"key":"ref_39","unstructured":"Drugs.com (2024, March 03). Stelara (Ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis. Available online: https:\/\/www.drugs.com\/newdrugs\/stelara-ustekinumab-approved-u-s-food-administration-pediatric-patients-active-psoriatic-arthritis-5867.html."},{"key":"ref_40","unstructured":"European Medicines Agency (2024, March 03). Stelara: Procedural Steps Taken and Scientific Information After the Authorisation. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/stelara-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf."},{"key":"ref_41","unstructured":"European Medicines Agency (2024, March 03). Taltz: Procedural Steps Taken and Scientific information after the Authorisation. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/taltz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf."},{"key":"ref_42","unstructured":"Drugs.com (2024, March 03). Taltz FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/taltz.html."},{"key":"ref_43","unstructured":"Drugs.com (2024, March 03). Lilly\u2019s Taltz (Ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis. Available online: https:\/\/www.drugs.com\/newdrugs\/lilly-s-taltz-ixekizumab-receives-u-s-fda-approval-pediatric-patients-moderate-severe-plaque-5194.html."},{"key":"ref_44","unstructured":"European Medicines Agency (2024, March 03). Cosentyx: Annex I: Summary of product characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"key":"ref_45","unstructured":"European Medicines Agency (2024, March 03). Cosentyx. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx."},{"key":"ref_46","unstructured":"Drugs.com (2024, March 03). Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis. Available online: https:\/\/www.drugs.com\/newdrugs\/novartis-cosentyx-receives-fda-approval-children-adolescents-moderate-severe-plaque-psoriasis-5547.html."},{"key":"ref_47","unstructured":"Drugs.com (2024, March 03). Novartis Cosentyx Receives FDA Approval for the Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis. Available online: https:\/\/www.drugs.com\/newdrugs\/novartis-cosentyx-receives-fda-approval-children-adolescents-enthesitis-related-arthritis-psoriatic-5761.html."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000503062","article-title":"Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children","volume":"236","author":"AlMutairi","year":"2020","journal-title":"Dermatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","article-title":"Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie","volume":"62","author":"Wagner","year":"2019","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: Update 2021","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1098332","DOI":"10.3389\/fped.2022.1098332","article-title":"Vaccinology in pediatric rheumatology: Past, present and future","volume":"10","author":"Bizjak","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12969-018-0231-3","article-title":"Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list","volume":"16","author":"Speth","year":"2018","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_55","unstructured":"Robert Koch-Institut (2024, February 01). Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut 2023. Available online: https:\/\/edoc.rki.de\/handle\/176904\/10636.4."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: A systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"ref_57","first-page":"934","article-title":"Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm\u2013Teil 1: Therapieziele und Therapieempfehlungen","volume":"19","author":"Nast","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study","volume":"25","author":"Torres","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1046306","DOI":"10.3389\/fphar.2023.1046306","article-title":"Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review","volume":"14","author":"Jahnich","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0043-116545","article-title":"S2k-Leitlinie zur Diagnostik, Pr\u00e4vention und Therapie der Tuberkulose im Kindes- und Jugendalter","volume":"71","author":"Brinkmann","year":"2017","journal-title":"Pneumologie"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00393-022-01274-6","article-title":"Consensus Statement der \u00d6sterreichischen Gesellschaften f\u00fcr Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder \u201ctargeted synthetic\u201d DMARDs (\u201cdisease modifying antirheumatic drugs\u201d)","volume":"82","author":"Rath","year":"2023","journal-title":"Z. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00393-009-0475-x","article-title":"Empfehlungen f\u00fcr das Tuberkulose-Screening vor Gabe von TNF-alpha-Inhibitoren bei rheumatischen Erkrankungen","volume":"68","author":"Diel","year":"2009","journal-title":"Z. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0043-105954","article-title":"S2k-Leitlinie: Tuberkulose im Erwachsenenalter","volume":"71","author":"Schaberg","year":"2017","journal-title":"Pneumologie"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:49Z","timestamp":1760113069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":64,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216307"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216307","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}